<table className="table"><caption><p>Medications for Weight Loss</p></caption><thead><tr><th colSpan="1" rowSpan="1"><p>Medication</p></th><th colSpan="1" rowSpan="1"><p>Mechanism of Action</p></th><th colSpan="1" rowSpan="1"><p>Total Body Weight Loss<sup>a</sup> (%) or Actual Weight Loss (kg)</p></th><th colSpan="1" rowSpan="1"><p>Common Adverse Effects<sup>b</sup></p></th><th colSpan="1" rowSpan="1"><p>Contraindications</p></th></tr></thead><tbody><tr className="group_1-1 row-odd"><td colSpan="1" rowSpan="1"><p>Semaglutide (weekly injection)</p></td><td colSpan="1" rowSpan="1"><p>GLP-1 receptor agonist; delays gastric emptying and alters hypothalamic signaling to reduce hunger</p></td><td colSpan="1" rowSpan="1"><p>10.8%<sup>c</sup></p></td><td colSpan="1" rowSpan="1"><p>Gastrointestinal upset, headache, nasopharyngitis</p></td><td colSpan="1" rowSpan="1"><p>MTC, MEN2, pregnancy</p></td></tr><tr className="group_1-2 row-even"><td colSpan="1" rowSpan="1"><p>Liraglutide (daily injection)</p></td><td colSpan="1" rowSpan="1"><p>GLP-1 receptor agonist; delays gastric emptying and alters hypothalamic signaling to reduce hunger</p></td><td colSpan="1" rowSpan="1"><p>4.81%<sup>d</sup></p></td><td colSpan="1" rowSpan="1"><p>Gastrointestinal upset, headache, nasopharyngitis, injection site reaction</p></td><td colSpan="1" rowSpan="1"><p>MTC, MEN2, pregnancy</p></td></tr><tr className="group_1-3 row-odd"><td colSpan="1" rowSpan="1"><p>Tirzepatide (weekly injection)</p></td><td colSpan="1" rowSpan="1"><p>Dual GIP/GLP-1 receptor agonist; delays gastric emptying and alters hypothalamic signaling to reduce hunger</p></td><td colSpan="1" rowSpan="1"><p>20.9%<sup>e</sup></p></td><td colSpan="1" rowSpan="1"><p>Gastrointestinal upset, injection site reaction, hypoglycemia</p></td><td colSpan="1" rowSpan="1"><p>MTC, MEN2, pregnancy</p></td></tr><tr className="group_1-4 row-even"><td colSpan="1" rowSpan="1"><p>Phentermine-topiramate ER (oral)</p></td><td colSpan="1" rowSpan="1"><p>Noradrenergic/GABA receptor activator and AMPA glutamate receptor inhibitor; suppresses appetite</p></td><td colSpan="1" rowSpan="1"><p>8.45%<sup>f</sup></p></td><td colSpan="1" rowSpan="1"><p>Paresthesias, dizziness, taste alterations, insomnia, constipation, dry mouth, tachycardia, cognitive changes</p></td><td colSpan="1" rowSpan="1"><p>Glaucoma, hyperthyroidism, pregnancy</p><p>Phentermine is contraindicated in patients with a history of cardiovascular disease (e.g., coronary artery disease, heart failure, uncontrolled hypertension)</p></td></tr><tr className="group_1-5 row-odd"><td colSpan="1" rowSpan="1"><p>Naltrexone-bupropion ER (oral)</p></td><td colSpan="1" rowSpan="1"><p>Opioid antagonist plus norepinephrine/dopamine uptake inhibitor; suppresses appetite</p></td><td colSpan="1" rowSpan="1"><p>3.01%<sup>g</sup></p></td><td colSpan="1" rowSpan="1"><p>Gastrointestinal upset, headache, dizziness, insomnia, dry mouth, tachycardia, hypertension, anxiety, tremor</p></td><td colSpan="1" rowSpan="1"><p>Opioid use or withdrawal, uncontrolled hypertension, history of seizures, eating disorder</p></td></tr><tr className="group_1-6 row-even"><td colSpan="1" rowSpan="1"><p>Orlistat (oral)</p></td><td colSpan="1" rowSpan="1"><p>Lipase inhibitor; decreases triglyceride absorption</p></td><td colSpan="1" rowSpan="1"><p>2.6 kg (5.8 lbs)<sup>h</sup></p></td><td colSpan="1" rowSpan="1"><p>Oily stools, increased defecation, fecal urgency/incontinence</p></td><td colSpan="1" rowSpan="1"><p>Pregnancy, malabsorption syndrome, cholestasis</p></td></tr><tr className="group_1-7 row-odd"><td colSpan="1" rowSpan="1"><p>Diethylpropion (oral)</p></td><td colSpan="1" rowSpan="1"><p>Suppresses appetite (FDA approved for 12 weeks' duration)</p></td><td colSpan="1" rowSpan="1"><p>6.6%<sup>i</sup></p></td><td colSpan="1" rowSpan="1"><p>Dizziness, dry mouth, stomach pain</p></td><td colSpan="1" rowSpan="1"><p>History of heart disease</p></td></tr><tr className="group_1-8 row-even"><td colSpan="1" rowSpan="1"><p>Phentermine (oral)</p></td><td colSpan="1" rowSpan="1"><p>Noradrenergic receptor activator; suppresses appetite (FDA approved for 12 weeks' duration)</p></td><td colSpan="1" rowSpan="1"><p>3.63%<sup>j</sup></p></td><td colSpan="1" rowSpan="1"><p>Tachycardia, increased blood pressure, cognitive changes</p></td><td colSpan="1" rowSpan="1"><p>Glaucoma, hyperthyroidism, pregnancy, history of cardiovascular disease (e.g., coronary artery disease, heart failure, uncontrolled hypertension)</p></td></tr></tbody></table>